Latest

Pharm Exec's Top 50 Companies 2018

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth.

C-Suite Personality: Fit for Future?

Exploring new character benchmarks for today’s pharma executives, and whether they have the transformational traits to lead through change.

Amryt Pharma: Realizing Rare Disease Treatments

Pharm Exec speaks with Joe Wiley, CEO of Amryt Pharma, who is steering a road-less-traveled path for a small pharma—building a sustainable, commercial infrastructure first, with the hopes of accelerating new rare disease drugs to the market.

US Maps Strategy to Reform Drug Pricing

Azar and Gottlieb out front in revising rebates, restructuring Medicare, and promoting competition.

Pharm Exec Video

The Fundamental Disconnect Between Pharma and Technology

Otsuka Pharmaceuticals' William Carson explains the growing pains the company and its technology partner went through in reaching FDA approval for their digital medicine system.

Pharma’s Data Tsunami Problem

William Carson, Otsuka Pharmaceuticals' president & CEO of development and commercialization, talks about the industry's challenges in tackling the huge amounts of collected data.

Healthcare Robotics: Meet Mabu Your Personal Health Companion

Take a sneak peek at what the future of home healthcare could look like with the use of robotics and artificial intelligence.

New & Noteworthy

Digital Health: Regulatory, Compliance, and Legal Challenges

Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.

Leveraging Lab Data in Advent of Personalized Marketing

Laboratory testing has become a critical access point for sales teams in the age of personalized medicine, writes Melissa Leonhauser.

Brands of the Year: Promise and Challenge

In its 12th annual feature, Pharm Exec profiles a new round of biopharma products that are making waves in five key areas in healthcare and R&D.

Patient Advocacy: an Overlooked Strategy for Achieving Equitable Market Success?

Ellen Coleman outlines the highlights of a recent webinar on ensuring that patient advocacy is a key element of a market access strategy.

Sales & Marketing

Leveraging Lab Data in Advent of Personalized Marketing

Laboratory testing has become a critical access point for sales teams in the age of personalized medicine, writes Melissa Leonhauser.

Building a Key Account Organization: 5 Power Questions

If companies are serious about building a sustainable organization for their employees and becoming a partner to key accounts, they need to be prepared to remodel their whole business around it, writes Miranda Wheatley Price.

Why "Episodes" Matter for Doctors

A customer "episode" is a key unit of management that can produce significant growth and cost savings, write Rafael Natanek and George Eliades.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

How to Run Your Biotech Like the Kraft Family Runs the New England Patriots

Jonathan Kraft shares his family's secrets on what it takes to lead a successful organization, while also creating lasting brand power.

What Can Pharmaceutical Companies do to Feel Better About Reputation?

Reputation Institute study finds that the reputation of pharma companies is in decline and might get worse before it gets better.

Insights for the Win

Lisa Henderson reports on the takeaways from last month's annual gathering of the Pharm Exec Editorial Advisory Board.

Piecing Together the Pricing Puzzle: The Midterm Elections

There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.

Asembia 2018: User-Friendly Urgency

Michelle Maskaly reports on the possibilities for high tech and the patient journey in specialty pharma, as discussed at the recent Asembia conference in Las Vegas.

Interviews

Analytics, AI, and the Internet of Things in the Real World

IBM Watson Health's Peter Brandsetter talks about how analytics, IoT, and AI are moving from buzzwords to real-world solutions with benefits that weren't possible just a few years ago.

Amryt Pharma: Realizing Rare Disease Treatments

Pharm Exec speaks with Joe Wiley, CEO of Amryt Pharma, who is steering a road-less-traveled path for a small pharma—building a sustainable, commercial infrastructure first, with the hopes of accelerating new rare disease drugs to the market.

Lessons on the Innovation Journey

Rani Therapeutics CEO Mir Imran recounts the lessons he's learned in founding more than 20 life sciences companies and developing more than 400 patents.

Regulatory

Digital Health: Regulatory, Compliance, and Legal Challenges

Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.

Piecing Together the Pricing Puzzle: The Midterm Elections

There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.

FDA Launches Overhaul of New Drug Review Program

Pressure to assess and approve a growing volume of promising new drugs and biologics in accelerated timeframes is prompting a major reorganization of CDER's Office of New Drugs.

From the Editor

Insights for the Win

Lisa Henderson reports on the takeaways from last month's annual gathering of the Pharm Exec Editorial Advisory Board.

So Much Depends on the Physician

Amid new efforts to inspire more physicians to engage their patients about clinical research, turning that vision into tangible gains in trial participation remains tricky.

lorem ipsum